Case Report: Anti-PL-12 Antisynthetase syndrome complicated by natural killer/T cell non-Hodgkin's lymphoma. [PDF]
Li K, Liang ME, Liu Y, Guo QY, Xu K.
europepmc +1 more source
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan +15 more
wiley +1 more source
Non-Hodgkin's lymphoma involving chronic difficult-to-heal wounds: A case report. [PDF]
Zhang PS +7 more
europepmc +1 more source
ABSTRACT Dermatitis herpetiformis (DH) is a rare, intensely pruritic cutaneous manifestation of celiac disease (CD), typically presenting with excoriated papulovesicular lesions on extensor surfaces. DH is associated with IgA autoantibodies against epidermal transglutaminase (eTG), which form granular immune deposits in the papillary dermis and induce ...
Jeffrey Damman +5 more
wiley +1 more source
Computational screening and in vitro evaluation of sphingosine-1-phosphate analogues as therapeutics for Non-Hodgkin's lymphoma. [PDF]
Al Awadh AA.
europepmc +1 more source
Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo
Summary Background and objectives Chronic pruritus (CP) and chronic prurigo (CPG, including prurigo nodularis) are prevalent, debilitating diseases with diverse comorbidities, including malignancies. This retrospective cohort study evaluated the prevalence and risk of lymphoma in CP and CPG patients, including key risk factors, and sex‐ and ancestry ...
Svenja Royeck +10 more
wiley +1 more source
Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma. [PDF]
Wang L +23 more
europepmc +1 more source
Summary Background Studies on the state of medical care for patients with cutaneous T‐cell lymphoma (CTCL) are limited. To date, only secondary data analyses are available for Germany. Patients and Methods Cross‐sectional study conducted over a one‐year recruitment period (01 March 2024 to 28 February 2025) in the dermatological department of a German ...
Inga Hansen‐Abeck +5 more
wiley +1 more source
Establishment and validation of a clinical threshold criteria for choosing PET imaging tracers for indolent non-Hodgkin's lymphoma. [PDF]
Yu X +7 more
europepmc +1 more source
The different face of skin‐rash induced by brentuximab vedotin
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri +11 more
wiley +1 more source

